Enbrel provides sustained clinical improvements for ankylosing spondylitis for up to 3 years
13th Nov 2006, 18:39 GMT
Amgen (NASDAQ: AMGN) announced patients with ankylosing spondylitis who received treatment with Enbrel (R) (etanercept) experienced sustained improvement in signs and symptoms, spinal mobility and physical function over 148 to 160 weeks of therapy, according to data from an ongoing open-label, multinational, phase 4 extension study presented at the American College of Rheumatology scientific meeting. These results are consistent with an ENBREL phase 3 clinical trial at 24 weeks.
Enbrel provides sustained clinical improvements for ankylosing spondylitis for up to 3 years related news:
- Enbrel provides sustained clinical improvements for ankylosing spondylitis for up to 3 years — EurekAlert! - Breaking News
- Data Shows ENBREL Provides Sustained Clinical Improvements For People With Ankylosing Spondylitis For Up To Three Years — Health News from Medical News Today
- Enbrel first biologic with up to 9 years rheumatoid arthritis safety, sustained efficacy data — EurekAlert! - Medicine and Health
- A Predictor Of Joint Damage In Ankylosing Spondylitis Identified — Health News from Medical News Today
- Amgen arthritis drug shows sustained safety and efficacy — Pharmaceutical Business Review Latest News
- Amgen Releases Long-Term Enbrel Data — Bio-Technology News from StratCenter.com
- OpenClinicaTM 2.0 Now Available - Numerous New Features and Increased Interoperability — Press Release and Top News From 24-7 Press Release Newswire
- Genentech to Buy Tanox for $919M and Amgen and Wyeth's ENBREL is the First Biologic to Publish Data Showing Safety and Sustained Efficacy — Financial News USA (OTC: FNWU)
- Sustained Response at Month 12 for Transgene's TG 4001 in HPV-Induced Precancerous Lesions of the Cervix and Next Clinical Development Steps — PR Newswire: All Releases
- NTSB Wants Improvements In Runway Safety — wnbc.com - Local News
Latest news from EurekAlert! - Medicine and Health:
- Enbrel first biologic with up to 9 years rheumatoid arthritis safety, sustained efficacy data
- UCSD computer scientist wins Young Investigator Award, research on snake venom proteins highlighted
- Why do insects like to eat some plants more than others?
- Opposites do not attract
- Wild gorillas carriers of an SIV virus close to the AIDS virus
- New data show ACTOS (pioglitazone HCl) halted progression of atherosclerosis as indicated by CIMT
- Pourquié lab identifies genes involved in formation of vertebral precursors
- Artificial cornea offers better results for infants, some blind patients
- Healthier kids just the click of a remote away
- Adolescents, risks and the pitfalls of rationality